Calcineurin/NFAT Signaling in Osteoblasts Regulates Bone Mass  by Winslow, Monte M. et al.
Developmental Cell 10, 771–782, June, 2006 ª2006 Elsevier Inc. DOI 10.1016/j.devcel.2006.04.006Calcineurin/NFAT Signaling in Osteoblasts
Regulates Bone MassMonte M. Winslow,1 Minggui Pan,2 Michael Starbuck,3
Elena M. Gallo,1 Lei Deng,3 Gerard Karsenty,3
and Gerald R. Crabtree1,4,*
1Program in Immunology
2Division of Oncology
Stanford University
Stanford, California 94305
3Department of Molecular and Human Genetics and
the Bone Disease Program of Texas
Baylor College of Medicine
Houston, Texas 77030
4Howard Hughes Medical Institute and
Departments of Pathology and Developmental Biology
Stanford University
Stanford, California 94305
Summary
Development and repair of the vertebrate skeleton re-
quires theprecise coordinationofbone-formingosteo-
blasts and bone-resorbing osteoclasts. In diseases
such as osteoporosis, bone resorption dominates
over bone formation, suggesting a failure to harmonize
osteoclast andosteoblast function. Here,we show that
mice expressing a constitutively nuclear NFATc1 vari-
ant (NFATc1nuc) in osteoblasts develop high bone
mass. NFATc1nuc mice have massive osteoblast over-
growth, enhancedosteoblast proliferation, andcoordi-
nated changes in the expression ofWnt signaling com-
ponents. In contrast, viable NFATc1-deficient mice
have defects in skull bone formation in addition to im-
paired osteoclast development. NFATc1nuc mice have
increased osteoclastogenesis despite normal levels
of RANKL and OPG, indicating that an additional
NFAT-regulated mechanism influences osteoclasto-
genesis in vivo. Calcineurin/NFATc signaling in osteo-
blasts controls the expression of chemoattractants
that attract monocytic osteoclast precursors, thereby
coupling bone formation and bone resorption. Our re-
sults indicate that NFATc1 regulates bone mass by
functioning in both osteoblasts and osteoclasts.
Introduction
Bone is a dynamic organ, undergoing remodeling
throughout life. The elaborate processes of bone forma-
tion and resorption result from the intricately coupled
actions of bone-forming osteoblasts (Harada and Ro-
dan, 2003; Karsenty and Wagner, 2002) and bone-
resorbing osteoclasts (Boyle et al., 2003). When these
two processes are not balanced and bone resorption
dominates over bone formation, osteoporosis results
(Zelzer and Olsen, 2003).
Osteoblasts and osteoclasts are derived from distinct
stem cell pools and serve opposite but coordinated
roles during bone remodeling. Osteoblasts are derived
*Correspondence: crabtree@stanford.edufrom multipotent mesenchymal progenitors and form
the proteinacious bone matrix and orchestrate the min-
eralization of this extracellular matrix (Zelzer and Olsen,
2003). Bone mass is regulated both by the number and
bone-forming activity of mature osteoblasts. Osteoblast
number is regulated by differentiation and proliferation,
and recent data have highlighted several signaling path-
ways and transcription factors that regulate bone mass
(Harada and Rodan, 2003; Karsenty and Wagner, 2002;
Zelzer and Olsen, 2003). The Wnt/wingless pathway is
an established regulator of morphogenesis, and human
and mouse studies have implicated this pathway as a
regulator of bone mass (Glass et al., 2005; Gong et al.,
2001; Kato et al., 2002).
Bone formation by osteoblasts is opposed by bone
resorption by osteoclasts, which develop from hemato-
poietically derived monocytic cells (Ash et al., 1980).
These osteoclast progenitors are recruited to the bone,
where they interact with osteoblasts. Chemokines play
a crucial role in recruitment and positioning of immune
cells in tissue microenvironments (Butcher, 1991). Nu-
merous monocyte chemoattractants have been identi-
fied, several of which have been implicated in osteoclast
progenitor recruitment (Graves et al., 1999; Posner et al.,
1997; Votta et al., 2000; Yu et al., 2003, 2004). By control-
ling cell positioning, chemokines may regulate the inter-
actions between osteoclast progenitors and osteoblasts
that are critical for osteoclast development. Osteoblasts
regulate osteoclastogenesis by providing differentiation
and survival signals through receptor activator of NFkB
(RANK) and monocyte colony stimulating factor receptor
(M-CSF receptor) (Lacey et al., 1998; Lagasse and
Weissman, 1997). Multiple levels of positive and negative
feedback balance the activities of osteoblasts and
osteoclasts and preserve the steady state of mineralized
bone (Boyle et al., 2003; Harada and Rodan, 2003; Kar-
senty and Wagner, 2002; Zelzer and Olsen, 2003).
NFAT transcriptional complexes were initially identi-
fied in T cells in an effort to define the biochemical path-
way that leads from the antigen receptor to the genes
that regulate T cell development and differentiation
(Shaw et al., 1988). In unstimulated cells, NFATc tran-
scription factors are highly phosphorylated and cyto-
plasmic. When a stimulus results in an increase in intra-
cellular calcium ([Ca2+]i), the heterodimeric serine/
threonine phosphatase calcineurin dephosphorylates
NFATc, resulting in an allosteric switch that exposes
a nuclear localization sequence and conceals a nuclear
export sequence (Beals et al., 1997; Crabtree and Olson,
2002). NFATc then translocates to the nucleus and binds
to specific regions in the promoters of target genes. DNA
binding requires a nuclear partner protein. The nuclear
import and activation of NFATc is opposed by rephos-
phorylation of NFATc by GSK3 and other NFAT kinases
and subsequent nuclear export (Crabtree and Olson,
2002). The regulation of NFATc by nuclear import, nu-
clear export, and the assembly with nuclear partners al-
lows many different pathways to influence NFAT activity.
In vivo studies have shown that calcineurin/NFAT sig-
naling is an important regulator of immune development
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772Figure 1. A Constitutively Active Cyclosporine-Resistant NFATc1 Is Expressed in Osteoblasts from NFATc1nuc Mice
(A) Design of the doxycycline-regulatable NFATc1nuc transgene.
(B) RT-PCR analysis of P4 calvaria, passage 2 in vitro-cultured osteoblasts, and in vitro-differentiated (5 days with RANKL and M-CSF) osteo-
clasts. GAPDH is a control for RT, and no-RT is a control for genomic DNA contamination.
(C) NFATc1 Western blot on protein from control and NFATc1nuc osteoblasts. NFATc1nuc (79 kDa) cannot be detected, indicating that its expres-
sion is much lower than that of endogenous NFATc1.
(D) IP Western shows expression of NFATc1nuc protein (HA-tagged) in calvaria extract.
(E) Increased NFAT activity in NFATc1nuc osteoblasts. NFATc1nuc is constitutively active and CsA insensitive (n = 3, mean 6 SD, *p < 0.01).
(F) Lateral and dorsal photos of 12-week-old control and NFATc1nuc mice. Arrowheads indicate visually apparent changes in facial structure in
NFATc1nuc mice.
(G) Representative X-ray of 11-week-old control and NFATc1nuc mice (n > 20).and function (Neilson et al., 2004; Peng et al., 2001;
Ranger et al., 1998; Winslow et al., 2006), cardiac devel-
opment (Chang et al., 2004), angiogenesis (Graef et al.,
2001), neural development and function (Graef et al.,
1999, 2003), muscle cell fusion (Horsley et al., 2003),
and chondrogenesis (Ranger et al., 2000). Patients
treated with the calcineurin inhibitors cyclosporine
(CsA) and FK506 develop osteopenia, and CsA-treated
patients have an increased incidence of fractures (Katz
and Epstein, 1992; Rodino and Shane, 1998; Sprague,
2000; Sprague and Josephson, 2004). These in vivo
effects may be due to inhibition of calcineurin in osteo-
blasts and osteoclasts, or they may be indirect, due to
calcineurin inhibition in other cell types. We generated
mouse lines that allowed us to assess the role of NFATc1
in osteoblasts and osteoclasts in vivo. Our results indi-
cate that calcineurin/NFAT signaling regulates osteo-
blast proliferation, osteoclast differentiation, and the
coordination of bone formation and resorption.
Results
To determine whether the NFAT pathway has the poten-
tial to function in osteoblasts, we examined the expres-
sion of various components of the NFAT pathway in os-
teoblasts. Primary mouse osteoblasts express NFATc1,
NFATc3, and NFATc4, but not NFATc2 (Figure S1; see
the Supplemental Data available with this article online).
The components of the heterodimeric calcineurin com-plex, calcineurin A and calcineurin b1, are also ex-
pressed in primary osteoblasts (unpublished data).
Pharmacological stimulation of osteoblasts or MC3T3-
E1 osteoblast-like cells leads to the calcineurin-depen-
dent dephosphorylation of NFATc1, NFATc1 nuclear
translocation, and increased NFAT transcriptional activ-
ity (Figure S1 and unpublished data). These results
prompted us to closely examine the role of NFAT signal-
ing in osteoblasts in vivo.
Generation of Mice Expressing Active NFATc1
in Osteoblasts
To characterize the function of NFATc1 in osteoblasts
in vivo, we generated mice expressing a constitutively
nuclear NFATc1 variant (NFATc1nuc) under the control
of the tetracycline-responsive operator (tetO) and bred
them to Em-tTA mice (Figure 1A) (Felsher and Bishop,
1999; Jain et al., 2002). In NFATc1nuc, the serines that
are dephosphorylated by calcineurin are mutated to al-
anines, rendering it constitutively nuclear, constitutively
active, and insensitive to nuclear kinases (Figure S2)
(Beals et al., 1997). In NFATc1nuc;Em-tTA mice (referred
to as NFATc1nuc mice), the tetracycline transactivator
(tTA) drives expression of NFATc1nuc in the thymus,
splenic lymphocytes, and bone (Figures 1B–1D and
unpublished data).
The expression of NFATc1nuc in bone could indicate
expression in osteoblasts, osteoclasts, or other cell lin-
eages.NFATc1nuc is expressed in osteoblasts, but not in
NFAT Regulates Bone Mass
773Figure 2. NFATc1nuc Mice Have Increased Bone Volume and Increased Osteoblast Number
(A) von Kossa/van Gieson-stained vertebrae from 4-week-old mice (bone is black). Bone volume/tissue volume (BV/TV) is shown (mean 6 SD,
***p < 0.0001).
(B) Vertebrae from 4-week-old mice treated with doxycycline throughout gestation and life (NFATc1nuc off; n = 4) have normal bone mass. Bone
volume/tissue volume (BV/TV) is shown (mean 6 SD).
(C) Increased osteoblast number in NFATc1nuc vertebrae from 4-week-old mice (n = 4). B, bone. Number of osteoblasts/bone perimeter (N.Ob/
B.Pm) and number of osteoblasts/tissue area (N.Ob/T.Ar) are shown (mean 6 SD, ***p < 0.0001).
(D) Disorganized calcein double labeling in NFATc1nuc vertebrae from 4-week-old mice (n = 4). Serum osteocalcin and alkaline phosphatase is
shown (mean 6 SD, **p < 0.001).
(E) Increased osteoclasts (TRAP stained) in vertebrae from 4-week-old NFATc1nuc mice (n = 4). Osteoclast surface/tissue volume (Oc.S/TV), os-
teoclast surface/bone surface (Oc.S/BS), bone surface/tissue volume (BS/TV), and number of osteoclasts/bone perimeter (N.Ob/B/Pr) are
shown. Serum creatinine (Cr) and deoxypyridonoline (Dpd) is also shown (mean 6 SD, *p < 0.01, **p < 0.001, ***p < 0.0001).in vitro-differentiated osteoclasts or monocytes from
NFATc1nuc mice (Figure 1B; Figure S2). Expression of
the 79 kDa NFATc1nuc protein in bone or primary osteo-
blasts from NFATc1nuc mice is below the level of detec-
tion by conventional NFATc1 or HA Western blotting.
NFATc1nuc was detectable by IP Western, indicating
that the transgene is expressed, but at a level well below
that of endogenous NFATc1 (Figures 1C and 1D). This
low level expression was functional, as NFATc1nuc oste-
oblasts have higher basal NFAT activity than control os-
teoblasts, and this NFAT activity was CsA resistant
(Figure 1E). Collectively, these data indicate that osteo-
blasts from NFATc1nuc mice express a constitutively ac-
tive NFATc1.NFATc1nuc Mice Have Increased Bone Mass
and Osteoblast Number
Visual, radiographic, and histological analyses indicated
that NFATc1nuc mice have increased bone (Figures 1F,
1G, and 2A). This high-bone mass phenotype was ob-
served in all NFATc1nuc;Em-tTA mice regardless of sex
or strain and in NFATc1nuc;Em-tTA from two independent
NFATc1nuc transgenic founder lines (Figures 1E, 1F, and
2A). High bone mass was not observed in NFATc1nuc
or Em-tTA single transgenic mice. Addition of doxycy-
cline to the animals’ drinking water (which turns off
NFATc1nuc expression by inhibiting the tTA; Furth
et al., 1994) prevented or reversed the high-bone mass
phenotype (Figure 2B; Figure S5). Additionally, a control
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774Figure 3. Increased Bone in NFATc1nuc Embryos and Increased Trabecular Number and Trabecular Thickness in P5 Mice
(A) von Kossa/van Giesen-stained E16.5 calvaria show increased mineralized bone (bone is black; n = 4).
(B) Increased bone in tibiae of P5 NFATc1nuc mice.
(C) Cross-section of the diaphysis of P5 tibia.
(D) Bone volume/tissue volume (BV/TV), connectivity (Conn. D.), trabecular number (Tb. N), and trabecular thickness (Tb. Th.) are shown (mean6
SD, ***p < 0.0001).transgenic mouse strain expressing wild-type NFATc1
(tetO-NFATc1wt) does not develop high bone mass (Fig-
ures S2 and S3). Therefore, the phenotype observed
in the NFATc1nuc mice is due to an increase in NFAT nu-
clear occupancy and NFAT activity.
Histological analysis of the vertebrae and tibia re-
vealed that 4-week-old NFATc1nuc mice have a 2-fold
increase in bone mass and an increase in osteoblast
number (Figure 2C and unpublished data). Osteoblasts
in the NFATc1nuc mice are in multiple layers in bone
that lacks normal trabecular order, while chondrocytes
within the growth plate appear normal (Figure 2C; Fig-
ures S4 and S5). Despite the remarkable increase in os-
teoblast number, we have never detected osteosarco-
mas in >200 NFATc1nuc mice.
Bone formation was assessed by in vivo calcein label-
ing and by measuring serum markers of bone formation.
NFATc1nuc mice have increased calcein incorporation
without consistent double labeling, reflecting the in-
creased number and disorganization of the osteoblasts
as well as the rapid osteogenesis that likely results in
woven bone (Figure 2D). Serum osteocalcin and alkaline
phosphatase are also significantly higher in NFATc1nuc
mice, confirming that bone formation is increased
(Figure 2D) (Kruse and Kracht, 1986).
Increased Osteoclast Number and Bone
Resorption in NFATc1nuc Mice
A second cellular phenotype was observed in the
NFATc1nuc mice. Although neither osteoclasts nor their
progenitors express NFATc1nuc, osteoclast number is
increased 4-fold in 4-week-old NFATc1nuc mice (Figures
1B and 2E; Figure S2). NFATc1nuc mice also have a
5-fold increase in urine deoxypyridinoline crosslinks,
a biochemical marker of osteoclast function (Robins
et al., 1994), indicating that there is increased osteoclast
function (Figure 2E). Thus, NFATc1nuc mice have both in-
creased bone formation and increased bone resorption.
Increased Bone Mass Early during Development
of NFATc1nuc Mice
To determine whether active NFATc1 alters the initiation
or extent of bone formation during embryogenesis, weanalyzed the skeletal elements of control and NFATc1nuc
embryos. Ossification of skeletal elements initiates at
the same developmental stage in control and NFATc1nuc
embryos. However, increased bone mass is apparent in
NFATc1nuc embryos at E16.5 by von Kossa staining and
at E17.5 by alizarin red staining. This increase in bone
mass includes skeletal elements formed by intramem-
branous and endochondral ossification (Figure 3A;
Figure S6). Five-day-old NFATc1nuc mice have greatly
increased trabecular bone volume and trabecular num-
ber in the diaphysal region (Figures 3B–3D). Importantly,
the trabecular thickness and connectivity are also
greater in tibiae from NFATc1nuc mice.
Active NFAT in Osteoblasts Is Sufficient to Produce
High Bone Mass
To determine whether the expression of active NFATc1
in osteoblasts is sufficient to drive the high-bone mass
phenotype, we transplanted E13.5 embryonic tibial and
femoral anlage (containing the cartilage scaffold and os-
teoblast progenitors) under the kidney capsule of adult
recipients. In this system, the wild-type host provides
the osteoclasts, the systemic environment, and the
bone marrow (Jochum et al., 2000). The NFATc1nuc
transplants had higher bone volume and connectivity
and more osteoblasts than control transplants (Figures
4A and 4B and unpublished data). These studies strongly
suggest that the high bone mass is due to NFATc1nuc ex-
pression in osteoblasts. Additionally, lethally irradiated
wild-type mice reconstituted with NFATc1nuc bone mar-
row do not develop high bone mass, indicating that hem-
atopoetically derived cells (including osteoclasts) are not
responsible for the high bone mass. These results indi-
cate that although the expression of NFATc1nuc in oste-
oblasts is extremely low, it is sufficient to drive the dra-
matic phenotype observed in the NFATc1nuc mice.
To determine the mechanism that leads to increased
osteoblast number, we assessed osteoblast prolifera-
tion and cell death. NFATc1nuc embryos have increased
osteoblast proliferation in the calvaria and mandibles at
E16.5 and E17.5. Osteoblast cell death in vitro and
in vivo was comparable (Figures 4C–4E; Figure S7).
The clear increase in osteoblast proliferation and bone
NFAT Regulates Bone Mass
775Figure 4. NFATc1nuc Mice Have Increased Osteoblast Proliferation In Vivo
(A) mCT of the transplanted fetal limb.
(B) Quantification of BV/TV and connectivity (Conn. D.) of transplanted femoral anlage (n = 4, mean 6 SD, **p < 0.01).
(C) Coronal sections of in vivo BrdU-labeled E16.5 calvaria. (Middle) Higher magnification of Box #1 in top panels. (Lower) Higher magnification
of the mandible.
(D) Quantification of percent BrdU+ osteoblasts in the area defined by Box #2 and within the mandible (n = 4 for each age, mean6 SD, *p < 0.01,
**p < 0.001).
(E) Quantification of osteoblast cell death in E16.5 calvaria (n = 4, mean 6 SD).
(F) E16.5 control and NFATc1nuc calvaria were TRAP stained for osteoclasts. Neither control nor NFATc1nuc calvaria have TRAP+ cells at this age.
The inlay shows P0 NFATc1nuc calvaria staining as a positive control. A scale bar is included in each panel.mass at E16.5 in NFATc1nuc mice precedes the increase
in osteoclast number, as TRAP+ cells were not present
in either control or NFATc1nuc skull bones at this age
(Figure 3F). This indicates that increased osteoclast
number and enhanced bone resorption do not drive
the increased osteoblast proliferation.
NFATc1nuc osteoblasts continue to express the
NFATc1nuc transgene throughout in vitro mineralization,
therefore, NFATc1nuc may function in mature bone-
forming osteoblasts (Figure S8). Control and NFATc1nuc
osteoblasts produce mineralized bone and induce alka-
line phosphatase activity comparably during in vitro
mineralization (Figure S8). Our results cannot rule out
the possibility that NFATc1nuc subtly enhances osteo-
blast function in vivo, but they indicate that active
NFATc1 does not alter their ability to differentiate and
form mineralized bone in vitro.
NFATc1 Is Required In Vivo for Osteoclastogenesis
To examine the function of endogenous NFATc1, we
generated and analyzed viable NFATc12/2;Tie2-
NFATc1+ mice. Expression of an NFATc1 transgene un-
der the control of the endothelial-specific Tie-2 promoter
rescues the lethal heart valve development defects in
NFATc12/2 embryos (Figure 5A) (Chang et al., 2004).
Neither osteoblasts nor osteoclast progenitors from
Tie2-NFATc1+ mice express the NFATc1 transgene
(Figure S9). NFATc12/2;Tie2-NFATc1+ mice appear nor-
mal at birth but gain weight slower than their littermates
and die before adulthood. These mice have greatly re-
duced osteoclastogenesis, as revealed by the absence
of tooth eruption, osteopetrosis, and very few small
TRAP+ cells (Figures 5B–5D). These results are consis-tent with previous in vitro and vivo results and indicate
that NFATc1 is required for osteoclast development (Hir-
otani et al., 2004; Humphrey et al., 2004; Ishida et al.,
2002; Takayanagi et al., 2002). The osteoclast defect
and the early lethality of NFATc12/2;Tie2-NFATc1+ mice
compromised our ability to closely analyze bone forma-
tion in adult mice. However, examination of skeletal
elements during development revealed delayed frontal,
parietal, and occipital bone formation in NFATc12/2;
Tie2-NFATc1+ mice, and these bones are thinner even
at 2 weeks of age (Figures 5E and 5F and unpublished
data). These results suggest a bone formation defect in
viable NFATc1-deficient mice.
Active NFATc1 Coordinately Regulates Genes
Critical for Wnt Signaling
To understand the mechanism by which active NFATc1
enhances osteoblast proliferation and leads to increased
osteoclastogenesis, we performed global gene expres-
sion profiling on control and NFATc1nuc postnatal day
4 (P4) calvaria. We chose to analyze whole P4 skull
bone in order to get a snapshot of the total bone genes
early in the development of this phenotype. Several
known osteoblast functional genes, growth factors,
and growth factor receptors are changed (Figure 6; Ta-
ble S1), reflecting a global change in the genetic
program that drives increased immature osteoblast
proliferation. Two established NFAT target genes,
DSCR1 and Egr2, are increased in NFATc1nuc bone
(Figure 6A). Interestingly, there is a coordinated change
in the expression of genes within the Wnt/wingless sig-
naling pathway: Wnt4 and Frizzled 9 are increased, while
the Wnt inhibitors Dickkopf 2 (DKK2) and secreted
Developmental Cell
776Figure 5. Viable NFATc12/2 Mice Lack Osteoclasts and Have Delayed Skull Bone Formation
(A) Design of the NFATc12/2;Tie2-NFATc1+ transgene to rescue heart valve development in NFATc1-deficient mice.
(B) Ventral view of 3-week-old skulls. The pink bracket highlights the lack of incisors in the NFATc12/2;Tie2-NFATc1+ mouse (n = 3). (Lower)
The lateral X-ray of the skull shows the lack of both upper and lower incisors (white brackets) and the absence of molars (white arrowhead) in
NFATc12/2;Tie2-NFATc1+ mice.
(C) mCT analysis of tibia shows osteopetrosis in NFATc12/2;Tie2-NFATc1+ mice.
(D) NFATc12/2;Tie2-NFATc1+ mice lack TRAP+ osteoclasts (n = 3).
(E) NFATc12/2;Tie2-NFATc1+ mice have delayed calvaria formation. Dorsal view of P4 whole calvaria (n = 3).
(F) Decreased bone in NFATc12/2;Tie2-NFATc1+ skulls. Comparable coronal sections of E16.5 frontal bones are shown (n = 3).frizzled-related protein 2 (sfrp2) are decreased (Figures
6A and 6C). Studies in both humans and mice have im-
plicated Wnt signaling in the regulation of bone mass
(Gong et al., 2001; Kato et al., 2002). These Wnt compo-
nents could function in either an autocrine or a paracrine
fashion to regulate osteoblast proliferation.
Expression of many other genes previously implicated
in osteoblast proliferation, differentiation, and function
is not changed (Table S2). Importantly, expression of
the key osteoblast transcription factor, Runx2, is similar
at the RNA and protein levels (Figure 6D; Table S2). Con-
sistent with the increased in vivo proliferation, many cell
cycle regulators are increased in NFATc1nuc calvaria
(Figures 4C, 4D, and 6B).
Increased Monocyte Chemoattractant Expression
in NFATc1nuc Bone
Several monocyte chemoattractants (CCL8/monocyte
chemoattractant protein-2 [MCP-2], CCL6/C10, and
CCL12/MCP-5) are increased in the NFATc1nuc calvaria
(Figure 6E). These chemokines may recruit monocytes
to bone, where interactions with osteoblasts allow these
precursors to differentiate into mature osteoclasts,
thereby balancing osteoblast number with osteoclast
differentiation. In support of this hypothesis, many
monocyte/osteoclast genes are increased in the
NFATc1nuc calvaria and these calvaria have increased
TRAP staining, consistent with increased osteoclasto-
genesis (Figures 6F and 7A).
While chemokines can control the recruitment and
localization of hematopoietic cells, the enhanced osteo-
clastogenesis in NFATc1nuc mice could also be driven by
other changes in osteoblast gene expression. Osteo-
blasts control the maturation of osteoclasts in vivo,
and coculture of osteoblasts with monocytes leads toosteoclast development in vitro (Takahashi et al.,
1988). We determined whether NFATc1nuc osteoblasts
have an enhanced ability to direct osteoclast develop-
ment in vitro. Cultured osteoblasts from control and
NFATc1nuc calvaria direct osteoclast differentiation
comparably in vitro (Figure 7B). Additionally, control
and NFATc1nuc calvaria express similar levels of the
key osteoclast differentiation and survival factors
RANKL, OPG, and M-CSF (Figure 7C). Control and
NFATc1nuc mice also have similar serum levels of RANKL
and OPG (Figure 7D). These results indicate that the
increase in osteoclastogenesis in NFATc1nuc mice is
not driven by changes in RANKL or OPG expression by
osteoblasts.
Active NFATc1 has been shown to be sufficient to
promote osteoclastogenesis of a monocyte cell line,
suggesting that the increased osteoclastogenesis in
NFATc1nuc mice could be due to expression of the trans-
gene in monocytes or osteoclasts (Hirotani et al., 2004).
Despite our inability to detect NFATc1nuc expression in
monocytes or osteoclasts, an extremely low level that
affects osteoclastogenesis in these mice could be pres-
ent. To address this, splenocytes from young control
and NFATc1nuc mice were cultured in vitro with RANKL
and M-CSF, and the number of multinucleated TRAP+
cells was determined after 5 days. Splenocytes from 4-
day-old mice were used because adult NFATc1nuc
mice have an altered bone marrow environment and ex-
tramedullary hematopoiesis in the spleen. Control and
NFATc1nuc splenocytes gave rise to comparable num-
bers of TRAP+ multinucleated cells in vitro, indicating
that these cells have an equivalent intrinsic potential to
become osteoclasts (Figure 7E). The differentiation of
these cells into osteoclasts was sensitive to the calci-
neurin inhibitor CsA, consistent with the absence of
NFATc1nuc expression (Figure 7E).
NFAT Regulates Bone Mass
777Figure 6. NFATc1nuc Mice Have Changes in Gene Expression Consistent with Increased Proliferation and Monocyte Recruitment
(A–F) (A, B, E, and F) Gene expression changes between control and NFATc1nuc calvaria expressed as fold change. (A) Osteoblast genes, (B) cell
cycle genes, (E) monocyte chemoattractants, and (F) monocyte genes. *Fold change is an average of two or more features for that gene. #Change
validated by RT-PCR on independent calvaria RNA. (C) RT-PCR verification of Wnt4, Frizzled9 (Fzd9), and DKK2 expression in NFATc1nuc and
control calvaria. A 2-fold dilution series is shown with GAPDH as a control. (D) Runx2 protein expression is unaltered in NFATc1nuc calvaria and
in vitro-cultured osteoblasts. Brg shows equal nuclear loading.CCL8 Is a Direct Target of Calcineurin/NFAT
Signaling
NFATc1nuc osteoblasts have an equivalent ability to di-
rect osteoclast development in vitro and express normal
levels of RANKL and OPG. NFATc1nuc mice have greatly
increased osteoclast numbers in vivo, suggesting that
active NFATc in osteoblasts may control an additional
regulator of osteoclastogenesis. Based on our gene ex-
pression data and the significant increase in osteoclasts
in calvaria from 4-day-old NFATc1nuc mice, we further
investigated the expression and regulation of the mono-
cyte chemoattractants. CCL8 was originally cloned from
an osteogenic sarcoma line, and both CCL8 and CCL12
have been shown to specifically attract monocytes
in vitro and in vivo (Sarafi et al., 1997; Van Coillie et al.,
1997; Van Damme et al., 1992). We first verified the in-
creased expression of CCL8 in calvaria from NFATc1nuc
mice by RT-PCR (Figure 7F), and then determined
whether NFAT could regulate CCL8 expression. The
50 flanking regions and introns of CCL8 are conserved
between multiple species and have many potential
NFAT binding sites. To create a reporter with all the con-
trol regions of endogenous CCL8, we inserted the lucif-
erase gene in-frame into the first exon. This reporter is
induced in osteoblasts by PMA/Ionomycin stimulation,
blocked by CsA, and upregulated by NFATc1nuc expres-
sion, suggesting that NFAT signaling directly regulates
CCL8 expression (Figures 7G and 7H).
Discussion
Bone is constantly resorbed and rebuilt; thus, the proper
regulation of bone mass requires the precise coordina-
tion of osteoblasts and osteoclasts. In osteoporosis,an imbalance between bone formation and bone resorp-
tion over many years leads to crippling consequences.
Our data indicate that calcineurin/NFAT signaling func-
tions in osteoblasts and osteoclasts to regulate bone
mass (Figure 7I). NFATc1 is essential for osteoclast line-
age specification, while active NFAT drives osteoblast
proliferation in vivo. Additionally, calcineurin/NFAT sig-
naling in osteoblasts enhances chemokine expression,
which may recruit osteoclast precursors to bone and
influence osteoclastogenesis.
NFATc1 Regulates Osteoblast Proliferation In Vivo
Our results indicate that mice expressing a low level of
active NFATc1 develop severe osteosclerosis caused
by a dramatic increase in osteoblast number. Several
lines of evidence indicate that active NFATc1 in osteo-
blasts is sufficient to direct osteoblast proliferation
in vivo. Embryonic tibial and femoral NFATc1nuc anlage
transplanted under the kidney capsule of wild-type mice
develop the high-bone mass phenotype. NFATc1nuc
was also expressed in thymic and splenic lymphocytes,
but T and B cells are not required for the high-bone mass
phenotype, as NFATc1nuc mice on TCRa2/2 (which lack
abT cells) or Rag22/2(which lack all T and B cells) back-
grounds still develop high bone mass (unpublished
data). Involvement of a gene at the transgene integration
site is excluded by the suppression of the phenotype by
doxycycline administration (transgene off), the lack of
high bone mass in Em-tTA and NFATc1nuc single trans-
genic mice, and the presence of high bone mass in two
independent NFATc1nuc mouse lines. Collectively, our
results indicate that NFATc1nuc directs osteoblast prolif-
eration (perhaps more exuberant osteoblast overgrowth
than any other genetically modified mouse) by slightly
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(A) Dorsal view of TRAP-stained whole P4 calvaria (n = 4). Major skull bones are indicated. fr, frontal; pa, parietal; oc, occipital.
(B) Coculture of control or NFATc1nuc osteoblasts with control bone marrow (BM) or splenocytes (Sp) leads to equivalent TRAP+ multinucleated
osteoclast development in vitro.
(C) Control and NFATc1nuc calvaria express similar levels of RANKL, OPG, and M-CSF as assessed by microarray. Data are the average of three
repeats and of multiple features for each gene.
(D) Similar serum levels of RANKL and OPG in control and NFATc1nuc mice.
(E) RANKL and M-CSF induce equivalent osteoclast development from control and NFATc1nuc splenocytes (Sp) in vitro. Osteoclast development
is sensitive to CsA (100 ng/ml).
(F) RT-PCR for CCL8 on control and NFATc1nuc calvaria. A 2-fold dilution series is shown with GAPDH as a control.
(G) MC3T3-E1 cells were transfected with pGL3.CCL8 with or without an NFATc1nuc expression plasmid. Expression of NFATc1nuc increased
basal CCL8 luciferase expression, which was not blocked by the calcineurin inhibitor CsA (100 ng/ml) (luciferase activity is normalized to renilla
luciferase, n = 3, mean 6 SD).
(H) CCL8 expression is activated by PMA/Ionomycin and is calcineurin dependant (n = 3, mean 6 SD).
(I) NFAT functions in both osteoblasts and osteoclasts to regulate bone mass. Small changes in the nuclear occupancy of NFATc1 lead to a
dramatic increase in osteoblast progenitor proliferation. Active NFATc1 also directs a genetic program that leads to monocyte recruitment.
Chemokines attract monocytes from the blood and surrounding tissue and position monocytes in close proximity to osteoblasts, where they
receive RANK and M-CSF receptor signaling. NFATc1 functions downstream of RANK in osteoclast progenitors and is indispensable for the
development of mature osteoclasts in vivo.enhancing the nuclear occupancy of NFATc1. This
observation indicates that subtle yet stable changes in
transcription factor activity can produce dramatic
effects.
Our gene expression profiling indicates that compo-
nents of the Wnt signaling pathway are coordinately
changed in NFATc1nuc calvaria. While the Wnt signaling
pathway may regulate osteoblast differentiation, prolif-
eration, and function, the signaling pathways that regu-late the expression of Wnt signaling components in os-
teoblasts are poorly defined. Our studies suggest that
NFAT signaling may coordinately alter Wnt4, Frizzled9,
and DKK2 expression, providing a potential mechanism
by which NFAT signaling regulates osteoblast prolifera-
tion. Additional studies will be required to determine
the extent to which enhanced Wnt signaling in vivo con-
tributes to the increased osteoblast number and high
bone mass in NFATc1nuc mice.
NFAT Regulates Bone Mass
779Osteopetrosis in Viable NFATc12/2 Mice
Viable NFATc1-deficient mice fail to develop mature os-
teoclasts. Gene-targeted mice that lack RANK or FcgRIII
and DAP12 fail to activate and induce NFATc1 and do
not develop mature osteoclasts, suggesting that
NFATc1 activation downstream of RANK may be critical
for osteoclastogenesis in vivo (Humphrey et al., 2004;
Ishida et al., 2002; Koga et al., 2004; Takayanagi et al.,
2002). NFATc1 autoregulation (Northrop et al., 1994) ap-
pears to be a necessary positively reinforcing feedback
loop, which likely explains the specific requirement
for NFATc1 during osteoclastogenesis (Asagiri et al.,
2005). The retroviral expression of active NFATc1 is suf-
ficient to drive the differentiation of a monocytic cell line
to osteoclasts in vitro (Hirotani et al., 2004). These data
indicate that NFATc1 plays a second role in regulating
bone mass by acting cell autonomously to regulate
osteoclastogenesis.
Active NFAT in Osteoblasts Increases
Osteoclastogenesis
NFATc1nuc mice have increased osteoclast number and
increased bone resorption. Several observations indi-
cate that this increase in osteoclast number is second-
ary to the expression of active NFATc1 in osteoblasts.
First, NFATc1nuc expression is undetectable in mono-
cytes or osteoclasts, and NFATc1nuc splenocytes do
not have enhanced osteoclastogenesis in vitro (Figures
1B and 7E; Figure S2). Second, the increased osteoblast
proliferation in NFATc1nuc mice precedes the increased
osteoclast number during embryogenesis (Figure 4F).
Third, transplanted NFATc1nuc fetal limbs have osteo-
clasts similar to untransplanted NFATc1nuc vertebrae
and thin trabeculae, indicating that there is increased
osteoclastogenesis in NFATc1nuc bone even in a situa-
tion where the osteoclast progenitors are wild-type
(Oc.S/BS is 6.11 6 2.02 and Oc.S/TV is 202.3 6 61.8
[n = 5]; see Figure 2I).
How does enhanced NFAT activity in osteoblasts en-
hance osteoclastogenesis? The expression of RANKL
and the soluble decoy receptor OPG are unchanged
in NFATc1nuc bones, and the ability of NFATc1nuc osteo-
blasts to direct osteoclast differentiation in vitro is com-
parable to that of control osteoblasts. These results
indicate that an additional mechanism regulates osteo-
clastogenesis in NFATc1nuc mice in vivo. Several mono-
cyte chemoattractants (CCL8, CCL6, and CCL12) are
upregulated in NFATc1nuc calvaria and could function
to control the recruitment and/or differentiation of these
osteoclast progenitors within bone. The addition of
CCL8 to in vitro osteoclastogenesis cultures did not al-
ter the development of osteoclasts, ruling out a direct
morphogenic function of CCL8 (data not shown). Che-
mokines and integrins coordinate the spatially and tem-
porally discrete patterns of cell migration in vivo, and
they would not be expected to influence in vitro cocul-
ture of monocytes on a confluent monolayer of osteo-
blasts (Butcher, 1991; Parfitt, 1998). Consistent with
the established ability of CCL8 and CCL12 to attract
monocytes in vivo, there was increased expression of
many monocyte genes in NFATc1nuc calvaria, indicating
that there was an increased number of monocytes within
this tissue. The dramatic increase in the expression of
several monocyte chemoattractants in NFATc1nuc cal-varia led us to test whether the calcineurin/NFAT path-
way regulates these chemokines. We found that calci-
neurin/NFAT signaling controls the expression of CCL8
in osteoblasts. Bone formation and bone resorption
are integrated processes, and the production of mono-
cyte chemoattractant proteins by osteoblasts may pro-
vide an additional level of coordination.
Regulation of Bone Mass by NFAT
Previous studies have attempted to determine the role
of the calcineurin/NFAT pathway in osteoblasts (Buchin-
sky et al., 1996; Cvetkovic et al., 1994; Fornoni et al.,
2001; Goodman et al., 2001; Klein et al., 1997; Koga
et al., 2005; McCauley et al., 1992; Movsowitz et al.,
1988; Tang et al., 2002). These studies have been con-
tradictory, potentially due to the systemic effects of
the injected calcineurin inhibitors, the systemic nature
of NFATc2 deficiency, and the excessively high concen-
trations of calcineurin inhibitors used in vitro. A recent
report describes a potential role for NFAT in regulating
osteoblast function (Koga et al., 2005). Their results
complement our findings and indicate that NFAT may
function at different stages to regulate osteoblast prolif-
eration and function, consistent with the sequential
roles of calcineurin/NFAT signaling in other cell types
(Crabtree and Olson, 2002).
The role of calcineurin/NFAT signaling in osteoblasts
and osteoclasts is interesting since these two cell types
oppose each other’s actions. We find that one function
of calcineurin/NFAT signaling in osteoblasts is to coor-
dinately regulate the expression of Wnt pathway and
cell cycle genes. Our studies also indicate that NFAT sig-
naling in osteoblasts directly activates genes encoding
chemokines. Thus, calcineurin/NFAT plays multiple
roles in osteoblasts and osteoclasts to regulate bone
mass.
Experimental Procedures
Generation of TetO-NFATc1nuc Mice
NFATc1nuc (mSRR+SP123) (Beals et al., 1997) was cloned into
pUD10-3 downstream of the hCMVTetO promoter. The transgene
was restriction digested to remove the plasmid backbone and was
purified, and pronuclear injection was performed with B6BAF1/J-
derived oocytes (Jackson). TetO-NFATc1wt mice were generated in
a similar manner. Genotype was determined by using the NFATc1nuc
specific primers 50-AAGAAGATGGTCCTGTCTGG-30 and 50-GTAG
TCTGGTACGTCGTAC-30. Em-tTA mice (FVB/N) (Felsher and Bishop,
1999), NFATc12/2;Tie2-NFATc1+ mice (Chang et al., 2004), Rag22/2
mice (Taconic), TCRa2/2 mice (Jackson), and SCID mice have been
previously described.
Protein and mRNA Analysis
For Western blot analyses, membranes were probed with anti-
NFATc1 (7A6; Pharmingen) and anti-actin (Sigma). IP Western was
performed using the HA-IP Western kit (Pierce). RNA was purified
using the total RNA kit (Amersham). NFATc1nuc was detected by
RT-PCR with the NFATc1nuc-specific PCR primers.
NFAT-Luciferase Activity and Cell Cultures
Primary mouse osteoblasts from P4 calvaria were cultured in aMEM
with 10% FCS and mineralized with 10 mg/ml b-glycerophosphate
and 50 mg/ml ascorbic acid as previously described (Ducy et al.,
1999). Primary osteoblasts were transfected with NFAT-GL3 (Shaw
et al., 1988) using FuGENE 6 Transfection Reagent (Roche). Trans-
fections were normalized by using renilla luciferase and the Dual
Luciferase Kit (Promega). The CCL8 luciferase construct has the
murine genomic regions from 2600 to +1 and from +1 to +1657 in
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cytes were cocultured with confluent calvarial osteoblasts in the
presence of 1028 M 1, 25 dihydroxyvitamin D3. After 5 days, cells
were fixed and TRAP stained and TRAP+ multinucleated cells were
counted as described (Glass et al., 2005). RANKL- and M-CSF-in-
duced in vitro osteoclastogenesis was performed as described
(Koga et al., 2004).
Histologic and Histomorphometric Analyses
Alcian blue/alizarin red staining was performed as previously de-
scribed (McLeod, 1980). Vertebrae were von Kossa/van Gieson
stained for BV/TV measurement, toluidine blue stained for osteo-
blasts, and TRAP stained for osteoclasts. Calcein double labeling
was performed as described (Vignery and Baron, 1980). Histomor-
phometric analyses were performed using the Osteomeasure
Analysis System (Osteometrics). To turn off transgene expression,
NFATc1nuc mice were treated with 200 mg/ml Doxycycline in their
drinking water. TRAP staining of whole calvaria was performed as
described (Meghji et al., 2001). For in vivo BrdU labeling, timed preg-
nant mice were injected intraperitoneally with 100 mg/kg bromo-
deoxyuridine (BrdU; Sigma) and harvested 3 hr later. Paraffin sec-
tions (7 mM) were stained with anti-BrdU and were hematoxylin
counterstained (Zymed). Deoxypyridinoline crosslinks were mea-
sured in morning urine and standardized to creatinine levels (Metra
Biosystems). Serum RANKL (R&D Systems), OPG (R&D Systems),
ALP, and osteocalcin (Biomedical Technologies) were measured.
All statistical differences were calculated by the Student’s t test.
Tibial and Femoral Anlage Transplant and mCT Analysis
Tibial and femoral anlagen from E13.5 embryos were transplanted
under the kidney capsules of SCID recipients. Transplants were an-
alyzed at 16 mm resolution 4 weeks after implantation by mCT with
a mCT40 scanner (Scanco Medical). mCT of P5 tibiae were analyzed
at 8 mm resolution.
Isolation of RNA, Hybridization, and Analysis of Microarrays
P4 NFATc1nuc and littermate control calvaria (4–6 calvaria per repli-
cate, three replicates per group) were lysed in Trizol reagent (Invitro-
gen). cDNA was synthesized (SuperScript Choice synthesis kit;
GIBCO-BRL) with T7-(dT)24 primers (Operon). Biotin-labeled cRNA
was synthesized (Enzo BioArray kit; Affymetrix) and fragmented ac-
cording to the manufacturer’s instructions. The GeneChip Mouse
Genome 430 2.0 Arrays (Affymetrix) were hybridized and scanned
by the Stanford Affymetrix Core Facility. Images were analyzed
with GCOS software with the all-probe sets scaling strategy. Data
analysis and comparisons between arrays were performed with
the Data Mining Tool.
Supplemental Data
Supplemental Data include nine figures and two tables and are avail-
able at http://www.developmentalcell.com/cgi/content/full/10/6/
771/DC1/.
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